On February 28, the NMPA website showed that CT Tianqing’s Class 1 innovative drug rovadicitinib tablets (Rovadicitinib, TQ05105) had been approved in China for first-line treatment of disease-related splenomegaly or symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
Rovadicitinib tablets are a first-in-class drug independently developed by CT Tianqing with a novel chemical structure. As a new oral JAK/ROCK inhibitor, rovadicitinib inhibits JAK family kinase activity and ROCK kinase activity, suppresses sustained abnormal activation of the JAK/STAT pathway, and at the same time inhibits ROCK2 to reduce STAT3 phosphorylation, thereby restoring immune balance.
According to the Insight database, this drug is the world’s first JAK/ROCK dual small-molecule inhibitor to enter the clinical stage. It was first registered for clinical trials in 2019 and first filed for marketing in July 2024. Myelofibrosis is the first approved indication, while a new indication for graft-versus-host disease has already entered Phase III clinical development and was included in the breakthrough therapy program by the CDE in August 2025. It has also been cleared to conduct Phase II clinical trials in the United States.
At the ESMO Congress 2024, CT Tianqing presented a mini-oral report on the randomized, double-blind, active-controlled pivotal Phase II study comparing rovadicitinib with hydroxyurea in intermediate- to high-risk myelofibrosis.
The study enrolled patients with intermediate-2 or high-risk myelofibrosis by DIPSS who had not previously received JAK inhibitors and had symptomatic splenomegaly. The primary endpoint was the proportion of patients achieving at least 35% reduction in spleen volume from baseline at Week 24, known as SVR35. A total of 107 subjects were enrolled, of whom 72 received rovadicitinib tablets and 35 were assigned to the control group. The results showed the following:
At Week 24, the SVR35 rate was clearly better in the rovadicitinib group than in the control group, at 58.33% versus 22.86%.
For best total symptom improvement, defined as the proportion of subjects achieving at least 50% reduction from baseline in total symptom score at any time point, rovadicitinib also outperformed the control group, at 77.78% versus 54.29%.
In terms of safety, the findings were similar to drugs against the same target, and no new safety signals were observed.
Myelofibrosis is a rare myeloproliferative disease characterized by proliferation of fibrous tissue in the bone marrow and abnormal hematopoiesis. It seriously affects patients’ quality of life and is generally associated with poor prognosis.
At present, overall treatment options for myelofibrosis remain limited. Before the advent of JAK inhibitors, hydroxyurea, glucocorticoids, androgens, immunomodulators, and other therapies were mainly used for symptomatic treatment. Although JAK inhibitors have since provided better targeted treatment options, current therapies still have shortcomings, and there remain many unmet clinical needs in myelofibrosis.
According to the Insight database, five targeted drugs had previously been approved globally for myelofibrosis, among which jaktinib and ruxolitinib have been approved for this indication in China.
The approval of rovadicitinib is expected to provide patients with a potentially beneficial innovative therapy. CT Tianqing has also built a deeper and more comprehensive layout in myelofibrosis, including later-line clinical research in patients who are resistant or refractory to ruxolitinib and accelerated studies of several combination regimens. Positive preliminary results have already been obtained with its in-house BET inhibitor TQB3617 and BCL-2 inhibitor TQB3909, suggesting encouraging prospects.